Balanced news tone
News Sentiment
GLUE sentiment intelligence
Monte Rosa Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-4.8% over one week, +26.4% over four weeks, trend active, and materially above fair value.
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 11:02
- Source
- MarketBeat
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:12
- Source
- Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 11:46
- Source
- The Globe and Mail
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 16:23
- Source
- MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 19:23
- Source
- simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE)
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 15:29
- Source
- Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 20:41
- Source
- Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9% - Should You Buy?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jul 2026 18:44
- Source
- MarketBeat
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:01
- Source
- GlobeNewswire
Monte Rosa lures 3 new hires with stock awards worth 18,025 options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Stock Titan
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- MarketBeat
Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 29 Jun 2026 22:50
- Source
- Motley Fool
GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Stock Titan
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 01:21
- Source
- simplywall.st
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% - Should You Buy?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- MarketBeat
GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jun 2026 18:00
- Source
- Insider Monkey
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 11:00
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 May 2026 00:24
- Source
- Simply Wall St.
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 15:15
- Source
- Zacks